nab-paclitaxel
Showing 1 - 25 of 325
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- Tucidinostat
- nab-paclitaxel
- (no location specified)
Nov 21, 2022
Pancreatic Cancer Trial in Boston, Philadelphia (Gemcitabine, Nab-paclitaxel, Paricalcitol)
Active, not recruiting
- Pancreatic Cancer
- Gemcitabine
- +3 more
-
Boston, Massachusetts
- +1 more
Jan 9, 2023
Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)
Recruiting
- Her-2 Negative Breast Cancer
- HRR Gene Mutation
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma Trial in Indianapolis (Lonsurf, Gemcitabine, Nab-Paclitaxel)
Active, not recruiting
- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma
- Lonsurf
- +2 more
-
Indianapolis, IndianaIndiana University Melvin & Bren Simon Cancer Center
Nov 29, 2022
Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,
Not yet recruiting
- Pancreatic Cancer, Stage IB
- +3 more
- sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Jan 4, 2023
Triple Negative Breast Cancer Metastatic Trial in Milano, Padova (Ceralasertib, Durvalumab, Nab-paclitaxel)
Recruiting
- Triple Negative Breast Cancer Metastatic
- Ceralasertib
- +2 more
-
Milano, Italy
- +1 more
Jan 16, 2023
Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic
Active, not recruiting
- Breast Cancer
- Pembrolizumab
- Nab-Paclitaxel
-
New York, New YorkNYU Perlmutter Cancer Center
Aug 5, 2022
Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)
Completed
- Breast Cancer
- Panitumumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 20, 2022
Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)
Active, not recruiting
- Breast Cancer
- Pembrolizumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 22, 2022
Solid Tumor, TNBC - Triple-Negative Breast Cancer Trial in Bengbu, Beijing (LAE005 + Afuresertib + Nab-Paclitaxel, LAE005 +
Recruiting
- Solid Tumor
- TNBC - Triple-Negative Breast Cancer
- LAE005 + Afuresertib + Nab-Paclitaxel
- +3 more
-
Bengbu, Anhui, China
- +1 more
May 19, 2022
NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- Pembrolizumab
- +4 more
-
Shanghai, ChinaZhongshan Hospital Fudan University
Aug 18, 2022
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma Trial in Beverly Hills, Los Angeles
Recruiting
- Advanced Pancreatic Adenocarcinoma
- +2 more
- Gemcitabine
- +2 more
-
Beverly Hills, California
- +1 more
Jun 16, 2022
NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- MPDL3280A
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 12, 2022
Metastatic Breast Cancer Trial in Shanghai (Sitravatinib, Tislelizumab, Nab-paclitaxel)
Recruiting
- Metastatic Breast Cancer
- Sitravatinib
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer
Jul 31, 2022
NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma
- Nab-paclitaxel
- +2 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Apr 26, 2022
Pancreatic Ductal Adenocarcinoma Trial in Saint Louis (BMS-813160, Nivolumab, Gemcitabine)
Active, not recruiting
- Pancreatic Ductal Adenocarcinoma
- BMS-813160
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Dec 8, 2022
Unresectable Pancreatic Carcinoma Trial in Herlev, Oslo (Tocilizumab, Gemcitabine, nab-Paclitaxel)
Active, not recruiting
- Unresectable Pancreatic Carcinoma
- Tocilizumab
- +2 more
-
Herlev, Denmark
- +1 more
Mar 15, 2022
Triple Negative Breast Cancer Trial in Shanghai (Cisplatin, Nab-paclitaxel, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Cisplatin
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 18, 2022
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV Trial (SBP-101, Nab-paclitaxel,
Not yet recruiting
- Pancreatic Cancer Metastatic
- +2 more
- SBP-101
- +3 more
- (no location specified)
Feb 21, 2022
Pancreatic Cancer Trial in Shanghai (SHR6390, Nab-paclitaxel, Gemcitabine)
Not yet recruiting
- Pancreatic Cancer
- SHR6390
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital Shanghai Jiaotong University School of Medicine
Jan 10, 2022
Pancreatic Adenocarcinoma, Metastatic Trial in Spain, United States (Nab-paclitaxel, Gemcitabine, VCN-01)
Not yet recruiting
- Pancreatic Adenocarcinoma
- Metastatic
- Nab-paclitaxel
- +2 more
-
New York, New York
- +7 more
Jan 3, 2023
Pancreas Cancer Trial in New York (Bethanechol, Gemcitabine, nab-paclitaxel)
Recruiting
- Pancreas Cancer
- Bethanechol
- +2 more
-
New York, New YorkColumbia University Medical Center
Feb 3, 2022